Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL11503668 | 0.89 | DPP4 (0.39) | DPP4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL23086044 | 0.79 | DPP4 (0.34) | DPP4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL23872426 | 0.79 | DPP4 (0.34) | DPP4 | |
| SCHEMBL23872424 | 0.79 | DPP4 (0.34) | DPP4 | |
| SCHEMBL6656541 | 0.79 | POLB (0.32) | POLBDPP4 | |
| SCHEMBL28539062 | 0.79 | POLB (0.32) | POLBDPP4 | |
| SCHEMBL23869968 | 0.77 | POLB (0.31) | POLB | |
| SCHEMBL26700648 | 0.77 | POLB (0.31) | POLB | |
| SCHEMBL14519699 | 0.77 | TP53 (0.33) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL18336693 | 0.77 | TP53 (0.33) | MEN1CYP3A4CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-111051432-B | Resin composition, method for producing resin film, and method for producing electronic device | 东丽株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11352342-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| US-11319312-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED | 2022-05-03 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210101893-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7176205-B2 | Bi-pyridinyl derivatives as NK-1 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | POLB 4054/4885DPP4 1158/4885CHRM2 2/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | POLB 4196/4885DPP4 2499/4885CHRM2 4721/4885 |
| US-11319312-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | POLB 4039/4885DPP4 769/4885CHRM2 2/4885 |
| US-11352342-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | POLB 4054/4885DPP4 1158/4885CHRM2 2/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | POLB 3689/4885DPP4 2266/4885CHRM2 592/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | POLB 2694/4885DPP4 3801/4885CHRM2 4359/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | POLB 3909/4885DPP4 1295/4885CHRM2 984/4885 |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | POLB 3070/4885DPP4 2139/4885CHRM2 490/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | POLB 2694/4885DPP4 3801/4885CHRM2 4359/4885 |
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | ACACA, ACACB, PC | POLB 1536/4885DPP4 829/4885CHRM2 4608/4885 |
| US-20210101893-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | POLB 4039/4885DPP4 769/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.